09:22 AM EST, 12/20/2024 (MT Newswires) -- Amgen ( AMGN ) , Eli Lilly ( LLY ) and Viking Therapeutics ( VKTX ) shares advanced 3.7%, 6.4% and 9.2%, respectively premarket Friday after Novo Nordisk's ( NVO ) CagriSema experimental obesity therapy fell short of expectations despite meeting the primary endpoint in a phase 3 trial.

Novo Nordisk ( NVO ) said that at 68 weeks, those on CagriSema experienced a weight loss of 22.7%, lower than the company's expected 25%. The company's shares slipped 21% pre-bell.

Novo Nordisk's ( NVO ) announcement comes a day after the US Food and Drug Administration said that Eli Lilly's ( LLY ) tirzepatide injection products Zepbound and Mounjaro are no longer in shortage.

Amgen ( AMGN ) and Viking Therapeutics ( VKTX ) are separately developing their own obesity drugs.